Pulsed Electromagentic Field in Haemophilia
- Conditions
- Hemophilia A
- Interventions
- Other: PEMF
- Registration Number
- NCT04590456
- Lead Sponsor
- Delta University for Science and Technology
- Brief Summary
To assess the effect of pulsed electero- magnetic field on swelling, range of motion and muscle strength of hemarthrotic knee joints of haemophilic subjects.
- Detailed Description
Haemophilia is an X-linked hereditary sex recessive disorder that impairs the body's ability to make blood clots. It includes two types: A (FVIII deficit factor) and B (IX deficit factor), depending on FVIII/FIX percentage in blood. The severity of haemophilia is classified into (severe: \<1%, moderate: 1-5%, and mild: \>5%). The prevalence of haemophilia A is 1: 5000 live births and haemophilia B is 1: 30000 live births.
This disease is characterized by hemarthrosis which is a hemorrhage in the locomotor system, mainly muscles and joints. Joint bleeding mainly occurs in knees, ankles and elbows. Haemorrhage in the muscle or joints accounts for 80% to 90% of all bleeding episodes in people with haemophilia. The most commonly affected joints in non-prophylaxis patients are the knees (45%) which is thought to be due to the large size of the synovial membrane and large rotational forces present. It is followed by the elbows (30%), ankles (15%), shoulders (3%), and wrists (2%). Bleeds are best detected by the patients themselves as bruising and swelling or described as a feeling of warmth or tingling within the joint preceding the clinical signs.
Pulsed electromagnetic field (PEMF) has been reported to be effective in reducing pain, healing of ulcers and promote bone healing, and treating osteoarthritis and inflammatory diseases of the musculoskeletal system. Also, it was reported that PEMF exposure significantly increases the anti-inflammatory effect, suggesting its potential therapeutic use in the treatment of inflammatory bone and joint disorders.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Male
- Target Recruitment
- 30
- type A hemophilia (moderate)
- free from any musculoskeletal deformities.
- patients who performed surgical procedures 6 weeks before conducting the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo group PEMF - PEMF group PEMF -
- Primary Outcome Measures
Name Time Method swelling basline and after 3 months of intervention. The swelling degree was detected by tape
- Secondary Outcome Measures
Name Time Method range of motion basline and after 3 months of intervention. Active knee range of flexion and extension were measured by electronic goniometer.
muscle strength basline and after 3 months of intervention. The peak concentric knee extensor (KE) and the peak concentric knee flexor (KF) was measured at 60/s angular speed by an isokinetic dynamometer.
Trial Locations
- Locations (1)
Delta University for Science and Technology
🇪🇬Gamasa, Dakahelia, Egypt